Patents by Inventor Hong M. Moulton
Hong M. Moulton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230212583Abstract: Disclosed herein are embodiments of a compound useful for treating or preventing SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a SARS-CoV-2 infection in the subject. The compound may comprise an oligomer comprising a nucleic acid base sequence that is antisense to a gene, pre-mRNA or mRNA in the subject, such as a gene, pre-mRNA or mRNA of transmembrane serine protease 2 (TMPRSS2). The compound also may comprise a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).Type: ApplicationFiled: October 13, 2022Publication date: July 6, 2023Applicants: Oregon State University, Philipps-Universität MarburgInventors: Eva Friebertshäuser, Hong M. Moulton, David A. Stein
-
Publication number: 20230203492Abstract: Disclosed herein are embodiments of a compound useful for treating or preventing betacoronavirus infections such as SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a betacoronavirus infection in the subject. The compound can comprise an oligomer comprising a nucleic acid base sequence that is antisense to at least a portion of a SARS-CoV-2 genomic RNA, and can comprise a sequence present in the 5? UTR and first 20 nt of coding sequence of the SARS-CoV-2 genomic RNA. The compound also can contain a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).Type: ApplicationFiled: November 7, 2022Publication date: June 29, 2023Applicants: Oregon State University, The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Hong M. Moulton, David Adam Stein, Heinrich Ulrich Feldmann, Kyle Ture Rosenke
-
Patent number: 11236329Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.Type: GrantFiled: April 24, 2014Date of Patent: February 1, 2022Assignee: Sarepta Therapeutics, Inc.Inventors: Hong M. Moulton, Ryszard Kole
-
Patent number: 10905782Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: GrantFiled: April 9, 2019Date of Patent: February 2, 2021Assignee: Sarepta Therapeutics, inc.Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, David A. Stein, Andrew D. Kroeker
-
Publication number: 20200016280Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: ApplicationFiled: April 9, 2019Publication date: January 16, 2020Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, David A. Stein, Andrew D. Kroeker
-
Patent number: 10300149Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: GrantFiled: January 10, 2017Date of Patent: May 28, 2019Assignee: SAREPTA THERAPEUTICS, INC.Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, David A. Stein, Andrew D. Kroeker
-
Publication number: 20170368203Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: ApplicationFiled: January 10, 2017Publication date: December 28, 2017Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, David A. Stein
-
Patent number: 9572899Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: GrantFiled: November 5, 2008Date of Patent: February 21, 2017Assignee: AVI BIOPHARMA, INC.Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, Andrew D. Kroeker, David A. Stein
-
Publication number: 20150080311Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.Type: ApplicationFiled: April 24, 2014Publication date: March 19, 2015Applicant: Sarepta Therapeutics, Inc.Inventors: Hong M. Moulton, Ryszard Kole
-
Patent number: 8741863Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.Type: GrantFiled: August 26, 2011Date of Patent: June 3, 2014Assignee: Sarepta Therapeutics, Inc.Inventors: Hong M. Moulton, Ryszard Kole
-
Patent number: 8357664Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5? or 3? terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3? terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.Type: GrantFiled: October 25, 2005Date of Patent: January 22, 2013Assignees: AVI BioPharma, Inc., M.I.T.Inventors: David A. Stein, Qing Ge, Jianzhu Chen, Patrick L. Iversen, Hong M. Moulton
-
Publication number: 20120058946Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.Type: ApplicationFiled: August 26, 2011Publication date: March 8, 2012Applicant: AVI BIOPHARMA, INC.Inventors: Hong M. Moulton, Ryszard Kole
-
Patent number: 8008469Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.Type: GrantFiled: November 15, 2007Date of Patent: August 30, 2011Assignee: AVI BioPharma Inc.Inventors: Dan V. Mourich, Hong M. Moulton, David J. Hinrichs, Patrick L. Iversen
-
Publication number: 20100016215Abstract: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary to the polyCUG or polyCCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA in DM1 or DM2, respectively. Conjugated to the oligonucleotide is a cell-penetrating peptide having the sequence (RXRR(B/X)R)2XB, where R is arginine; B is ?-alanine; and each X is —C(O)—(CH2)n—NH—, where n is 4-6. The antisense compound is effective to selectively block the sequestration of muscleblind-like 1 protein (MBNL1) and/or CUGBP, in heart and quadricep muscle in a myotonic dystrophy animal model.Type: ApplicationFiled: June 26, 2009Publication date: January 21, 2010Applicant: AVI BioPharma, Inc.Inventors: Hong M. Moulton, Ryszard Kole
-
Publication number: 20090099066Abstract: Cell-penetrating peptides useful for targeting a therapeutic compound to a selected mammalian tissue, methods for their identification, methods of forming conjugate compounds containing such peptides, and conjugates formed thereby are disclosed. The cell-penetrating peptides are 8 to 30 amino acid residues in length and consist of subsequences selected from the group consisting of RXR, RX, RB, and RBR; where R is arginine, B is ?-alanine, and each X is independently —C(O)—(CHR1)n—NH—, where n is 4-6 and each R1 is independently H or methyl, such that at most two R1's are methyl. In one embodiment, X is a 6-aminohexanoic acid residue.Type: ApplicationFiled: June 30, 2008Publication date: April 16, 2009Applicant: AVI BioPharma, Inc.Inventors: Hong M. Moulton, Patrick L. Iversen
-
Publication number: 20090082547Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: ApplicationFiled: November 5, 2008Publication date: March 26, 2009Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, Andrew D. Kroeker, David A. Stein
-
Patent number: 7468418Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: GrantFiled: April 29, 2004Date of Patent: December 23, 2008Assignee: AVI BioPharma., Inc.Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, Andrew D. Kroeker, David A. Stein
-
Publication number: 20040265879Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.Type: ApplicationFiled: April 29, 2004Publication date: December 30, 2004Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, Andrew D. Kroeker, David A. Stein